Fudan University Shanghai Cancer Center Archives

Fudan University Shanghai Cancer Center

Management of mCRPC in China

Posted by Bo Dai, MD, PhD | Jul 2020

Bo Dai, MD, PhD, Chief Physician and Director of the Department of Urology at Fudan University Shanghai Cancer Center, gives an overview of how metastatic castration-resistant prostate cancer (mCRPC) is managed in China. He explains that docetaxel, abiraterone, and enzalutamide are the only treatments available in China despite the proven effectiveness of other drug treatments. He references the PROfound study, which proved the effectiveness of olaparib, an FDA-approved drug which is available for metastatic ovarian cancer, but not mCRPC as of yet. Dr. Dai also reviews unmet treatment needs, including a lack of knowledge of the optimal treatment sequence, a need for overall survival improvement in the population of mCRPC patients in China, a lack of treatment urgency, and a lack of treatment affordability. He then shares data from Chinese studies on abiraterone and GT0918, which have both been found to produce positive results in patients. Dr. Dai concludes by discussing how abiraterone has become the most common mCRPC drug treatment due to it being produced in China.

Epidemiology & Genomics of Prostate Cancer in Asian Men

Posted by Yao Zhu, MD, PhD | Jun 2020

In conversation with Peter K.F. Chiu, MD, PhD, FRCSEd, Honorary Clinical Assistant Professor and Associate Consultant in the Division of Urology at the Chinese University of Hong Kong, Yao Zhu, MD, PhD, attending urologist at Fudan University Shanghai Cancer Center and Associate Professor in Oncology at Shanghai Medical College, discusses the increasing number of deaths from prostate cancer in East Asia, emphasizing the need to develop Asian-specific genetic risk models. Dr. Zhu notes that while data on non-Western populations has been relatively limited to this point, there appear to be numerous differences in prostate cancer-related mutations between East Asian men and Western men, including lower rates of TMPRSS2-ERG fusion and PTEN deletion, and increased prevalence of FOXA1, SPOP, CHD1, and BRCA2. He also observes that there are pharmacogenomic implications to differences in testosterone metabolism-related genes between East Asian and Western men.